Singular Genomics Systems

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Singular Genomics Systems reports Q1 loss but anticipates G4X launch

Singular Genomics Systems faces financial challenges with negative gross profit and a net loss in Q1 2024, but the G4X spatial sequencer holds promise for addressing spatial sequencing limitations. The company is strategically positioning itself for the commercial launch of G4X in 2025.

Singular Genomics reports revenue growth amidst operational challenges and opportunities

Singular Genomics Systems showed mixed financial performance in Q2 2024, with revenue growth but negative gross profit.
The company's focus on innovation, cost management, and product development positions it for future growth opportunities.
Opportunities in the G4X technology and services program offer potential for revenue expansion and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer, David Barker and Andrew Spaventa in June 2016 and is headquartered in San Diego, CA.

Fireside chat now scheduled for 8:00am PT on Thursday, August 11, 2022 Fireside chat now scheduled for 8:00am PT on Thursday, August 11, 2022

Singular Genomics Announces Rescheduled Presentation Time at the UBS Genomics 2.0 and MedTech Innovations Summit

The company further expanded its commercial leadership team with the appointment of Jeff Bullard as Head of Sales for North America The company further expanded its commercial leadership team with the appointment of Jeff Bullard as Head of Sales for North America

Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California.

Singular Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

Similar Genomics Systems (OMIC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Similar Genomics Systems (OMIC) Could be Great Choice for a Bottom Fisher

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 43rd Annual Global Healthcare Conference.

Singular Genomics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Agenus

Invitae

Our roundtable found three biotechs with a nice cash cushion.

3 Biotech Stocks With a Cash Pile Higher Than Their Valuations

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations Drew Spaventa - Founder and Chief Executive Officer Dalen Meeter - Head, Finance Eli Glezer - Founder and Chief Scientific Officer Conference Call Participants Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America John Sourbeer - UBS Tom Stevens - Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Singular Genomics' First Quarter 2022 Earnings Conference Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Philip Taylor.

Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q1 2022 Results - Earnings Call Transcript

Similar Genomics Systems (OMIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Similar Genomics Systems (OMIC) Upgraded to Buy: Here's What You Should Know

DocGo

Elanco Animal Health Inc

Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.

3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1

LA JOLLA, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2022 after the market close on Tuesday, May 10, 2022. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Singular Genomics Systems, Inc. to Report First Quarter 2022 Financial Results on May 10, 2022

Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q4 2021 Results - Earnings Call Transcript

LA JOLLA, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2021.

Singular Genomics Systems, Inc. Reports Recent Highlights, Fourth Quarter and Full Year 2021 Financial Results

This partnership integrates G4's accuracy, speed, flexibility and power with the QIAseq DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers This partnership integrates G4's accuracy, speed, flexibility and power with the QIAseq DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers

Singular Genomics Partners with QIAGEN to Enable QIAseq Kits for the G4 Sequencing Platform

This collaboration integrates G4's accuracy, speed, flexibility and power with the KAPA DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers This collaboration integrates G4's accuracy, speed, flexibility and power with the KAPA DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers

Singular Genomics G4 Sequencing Platform Shows High Performance with KAPA Library Preparation Kits

4D Molecular Therapeutics

First Watch Restaurant Group

NerdWallet

PROCEPT BioRobotics Corp

VectivBio Holding AG

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last year.

6 Underperforming IPO Stocks To Buy On The Dip

This partnership integrates G4's accuracy, speed, flexibility and power with the NEBNext DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers This partnership integrates G4's accuracy, speed, flexibility and power with the NEBNext DNA and RNA Library Prep Kits to empower high-quality, established workflows for customers

Singular Genomics Partners with New England Biolabs® to Enable NEBNext® Kits for the G4 Sequencing Platform

This partnership integrates G4's accuracy, speed, flexibility and power with Lexogen's expertise in RNA library preparation kits to empower specialized workflows for customers. This partnership integrates G4's accuracy, speed, flexibility and power with Lexogen's expertise in RNA library preparation kits to empower specialized workflows for customers.

Singular Genomics Partners with Lexogen to Enable RNA Library Prep for the G4 Sequencing Platform

Singular Genomics Systems Inc (NASDAQ:OMIC) launched the G4 system in late December and has begun taking orders, with shipments expected to commence in the second quarter of 2022, according to BofA Securities. The Singular Genomics Systems Analyst: Michael Ryskin upgraded the rating for Singular Genomics Systems from Neutral to Buy, while keeping the price target unchanged at $21.

Singular Genomics G4 Launch Impresses BofA Analyst: What's Next?

Management to Discuss the Launch of the G4 Sequencing Platform Management to Discuss the Launch of the G4 Sequencing Platform

Singular Genomics Systems, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment.

Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D.

This partnership will help biomedical researchers access and analyze data from Singular Genomics systems and easily collaborate on the cloud using a secure, scalable and open source informatic platform This partnership will help biomedical researchers access and analyze data from Singular Genomics systems and easily collaborate on the cloud using a secure, scalable and open source informatic platform

Singular Genomics and Broad Institute Partner to Integrate Advanced Sequencing Technology with the Terra Data Platform

– Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while offering flexible run capacity – – Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while offering flexible run capacity –

Singular Genomics Launches the G4 Sequencing Platform

Singular Genomics Systems, Inc. (OMIC) CEO Drew Spaventa on Q3 2021 Results - Earnings Call Transcript

LA JOLLA, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.

Singular Genomics Systems, Inc. Reports Recent Highlights and Third Quarter Financial Results

LA JOLLA, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company focused on delivering genomic technologies for the advancement of science and medicine, today announced that it will report financial results for the third quarter of 2021 after the market close on Tuesday, November 9, 2021. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

News for Singular Genomics Systems Stock (OMIC)